Literature DB >> 33735191

Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data.

Dirk Weyhe1, Dennis Obonyo1, Verena Nicole Uslar1, Ingo Stricker2, Andrea Tannapfel2.   

Abstract

Factors for overall survival after pancreatic ductal adenocarcinoma (PDAC) seem to be nodal status, chemotherapy administration, UICC staging, and resection margin. However, there is no consensus on the definition for tumor free resection margin. Therefore, univariate OS as well as multivariate long-term survival using cancer center data was analyzed with regards to two different resection margin definitions. Ninety-five patients met inclusion criteria (pancreatic head PDAC, R0/R1, no 30 days mortality). OS was analyzed in univariate analysis with respect to R-status, CRM (circumferential resection margin; positive: ≤1mm; negative: >1mm), nodal status, and chemotherapy administration. Long-term survival >36 months was modelled using multivariate logistic regression instead of Cox regression because the distribution function of the dependent data violated the requirements for the application of this test. Significant differences in OS were found regarding the R status (Median OS and 95%CI for R0: 29.8 months, 22.3-37.4; R1: 15.9 months, 9.2-22.7; p = 0.005), nodal status (pN0 = 34.7, 10.4-59.0; pN1 = 17.1, 11.5-22.8; p = 0.003), and chemotherapy (with CTx: 26.7, 20.4-33.0; without CTx: 9.7, 5.2-14.1; p < .001). OS according to CRM status differed on a clinically relevant level by about 12 months (CRM positive: 17.2 months, 11.5-23.0; CRM negative: 29.8 months, 18.6-41.1; p = 0.126). A multivariate model containing chemotherapy, nodal status, and CRM explained long-term survival (p = 0.008; correct prediction >70%). Chemotherapy, nodal status and resection margin according to UICC R status are univariate factors for OS after PDAC. In contrast, long-term survival seems to depend on wider resection margins than those used in UICC R classification. Therefore, standardized histopathological reporting (including resection margin size) should be agreed upon.

Entities:  

Year:  2021        PMID: 33735191      PMCID: PMC7971889          DOI: 10.1371/journal.pone.0248633

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  51 in total

1.  A novel approach to the intraoperative assessment of the uncinate margin of the pancreaticoduodenectomy specimen.

Authors:  Mahmoud A Khalifa; Vlad Maksymov; Corwyn H Rowsell; Sherif Hanna
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

Review 2.  Pathology handling of pancreatoduodenectomy specimens: Approaches and controversies.

Authors:  María Del Carmen Gómez-Mateo; Luis Sabater-Ortí; Antonio Ferrández-Izquierdo
Journal:  World J Gastrointest Oncol       Date:  2014-09-15

3.  Resection margin clearance in pancreatic cancer after implementation of the Leeds Pathology Protocol (LEEPP): clinically relevant or just academic?

Authors:  Florian Gebauer; Michael Tachezy; Yogesh K Vashist; Andreas H Marx; Emre Yekebas; Jakob R Izbicki; Maximilian Bockhorn
Journal:  World J Surg       Date:  2015-02       Impact factor: 3.352

Review 4.  Current standards of surgery for pancreatic cancer.

Authors:  N Alexakis; C Halloran; M Raraty; P Ghaneh; R Sutton; J P Neoptolemos
Journal:  Br J Surg       Date:  2004-11       Impact factor: 6.939

5.  Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience.

Authors:  Axel Richter; Marco Niedergethmann; Jörg W Sturm; Dietmar Lorenz; Stefan Post; Michael Trede
Journal:  World J Surg       Date:  2003-02-27       Impact factor: 3.352

6.  Margin clearance and outcome in resected pancreatic cancer.

Authors:  David K Chang; Amber L Johns; Neil D Merrett; Anthony J Gill; Emily K Colvin; Christopher J Scarlett; Nam Q Nguyen; Rupert W L Leong; Peter H Cosman; Mark I Kelly; Robert L Sutherland; Susan M Henshall; James G Kench; Andrew V Biankin
Journal:  J Clin Oncol       Date:  2009-04-27       Impact factor: 44.544

7.  Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients.

Authors:  Jonathan E Lim; Michael W Chien; Craig C Earle
Journal:  Ann Surg       Date:  2003-01       Impact factor: 12.969

8.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.

Authors:  John P Neoptolemos; Deborah D Stocken; Helmut Friess; Claudio Bassi; Janet A Dunn; Helen Hickey; Hans Beger; Laureano Fernandez-Cruz; Christos Dervenis; François Lacaine; Massimo Falconi; Paolo Pederzoli; Akos Pap; David Spooner; David J Kerr; Markus W Büchler
Journal:  N Engl J Med       Date:  2004-03-18       Impact factor: 91.245

9.  Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin.

Authors:  Fiona Campbell; Richard A Smith; Philip Whelan; Robert Sutton; Michael Raraty; John P Neoptolemos; Paula Ghaneh
Journal:  Histopathology       Date:  2009-09       Impact factor: 5.087

10.  Resection of the mesopancreas (RMP): a new surgical classification of a known anatomical space.

Authors:  Ines Gockel; Mario Domeyer; Tanja Wolloscheck; Moritz A Konerding; Theodor Junginger
Journal:  World J Surg Oncol       Date:  2007-04-25       Impact factor: 2.754

View more
  2 in total

1.  Diagnostic Accuracy of CT for Evaluating Circumferential Resection Margin Status in Resectable or Borderline Resectable Pancreatic Head Cancer: A Prospective Study Using Axially Sliced Surgical Pathologic Correlation.

Authors:  Ji Hoon Park; Yoo-Seok Yoon; Seungjae Lee; Hae Young Kim; Ho-Seong Han; Jun Suh Lee; Won Chang; Haeryoung Kim; Hee Young Na; Seungyeob Han; Kyoung Ho Lee
Journal:  Korean J Radiol       Date:  2022-01-06       Impact factor: 3.500

Review 2.  Prognostic Impact of Resection Margin Status on Distal Pancreatectomy for Ductal Adenocarcinoma.

Authors:  Maia Blomhoff Holm; Caroline Sophie Verbeke
Journal:  Curr Oncol       Date:  2022-09-14       Impact factor: 3.109

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.